閱文(00772.HK):中國電影市場復甦領先全球 行業對公司IP需求加快
閱文集團(00772.HK)去年有關收購新麗傳媒的商譽及商標權的減值撥備分別為40.15億元人民幣(下同)及3.9億元,加上修改新麗傳媒的獲利計酬機制導致的公允價值虧損淨額約6.04億元等,管理層在業績電話會議上解釋,每年或每半年都會進行相關評估,按行業情況等決定是否需要進行減值。
管理層續指,去年因疫情關係閱文的IP相關產業無論電影、劇集等都受到影響,目前來看中國電影市場復甦領先全球,而今年春節檔期電影票房表現強勁,感受到文化娛樂行業加快,而行業對閱文的IP需求亦加速,雖然現時難準確預測疫情及行業復甦進展,但大趨勢對IP、授權等看法樂觀。(el/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.